Show simple item record

dc.contributor.authorSaadoun, David
dc.contributor.authorEmmi, Giacomo
dc.contributor.authorHATEMİ, GÜLEN
dc.contributor.authorSEYAHİ, EMİRE
dc.contributor.authorPrisco, Domenico
dc.contributor.authorBettiol, Alessandra
dc.contributor.authorALİBAZ ÖNER, FATMA
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.date.accessioned2023-10-10T12:26:45Z
dc.date.available2023-10-10T12:26:45Z
dc.date.issued2023
dc.identifier.citationBettiol A., ALİBAZ ÖNER F., DİRESKENELİ R. H., HATEMİ G., Saadoun D., SEYAHİ E., Prisco D., Emmi G., "Vascular Behcet syndrome: from pathogenesis to treatment", NATURE REVIEWS RHEUMATOLOGY, cilt.19, sa.2, ss.111-126, 2023
dc.identifier.issn1759-4790
dc.identifier.othervv_1032021
dc.identifier.otherav_206dba69-0176-40dc-a544-7a883a75c4c4
dc.identifier.urihttp://hdl.handle.net/20.500.12627/190088
dc.identifier.urihttps://doi.org/10.1038/s41584-022-00880-7
dc.description.abstractBehcet syndrome is a rare, chronic inflammatory disease of unknown aetiopathogenesis, most commonly presenting with mucocutaneous and ocular manifestations. Vascular involvement, most frequently superficial vein and deep vein thrombosis, can occur in up to 50% of patients with Behcet syndrome. Venous thrombosis at atypical sites (inferior and superior vena cava, suprahepatic veins with Budd-Chiari syndrome, portal vein, cerebral sinuses and right atrium and/or ventricle) and arterial involvement (mostly in situ thrombosis and aneurysms of the pulmonary arteries, as well as aneurysms of the abdominal aorta, and peripheral and visceral arteries) are also unique features of Behcet syndrome. Behcet syndrome is considered a natural model of inflammation-induced thrombosis in humans, with an impaired immune-inflammatory response rather than traditional cardiovascular risk factors contributing to thrombogenesis. Specifically, neutrophil hyperactivation and neutrophil-mediated mechanisms of damage directly promote endothelial dysfunction, platelet activation and thrombogenesis in Behcet syndrome. This unusual pathogenesis directly determines the treatment approach, which relies mostly on immunosuppressants rather than anticoagulants for treatment of thrombosis and for secondary prevention. This Review discusses the main histopathological, pathogenetic and clinical aspects of vascular Behcet syndrome, addressing their implications for therapeutic management. Future perspectives in terms of pathogenetic studies, disease monitoring and treatment strategies are also discussed.
dc.language.isoeng
dc.subjectRomatoloji
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleVascular Behcet syndrome: from pathogenesis to treatment
dc.typeMakale
dc.relation.journalNATURE REVIEWS RHEUMATOLOGY
dc.contributor.departmentUniversity of Florence , ,
dc.identifier.volume19
dc.identifier.issue2
dc.identifier.startpage111
dc.identifier.endpage126
dc.contributor.firstauthorID4309638


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record